Myriad To Present Seven Clinical Studies At The Annual Clinical Genetics Meeting

SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee.

"We believe clinical research is vital to advance the science surrounding hereditary cancer and genetic testing, and we are committed to sharing timely and accurate information about our research with the scientific and medical communities," said Richard Wenstrup, chief medical officer at Myriad. "Myriad will continue to be a pioneer in hereditary cancer testing, especially as we look to improve patient care with our next-generation, myRisk™ Hereditary Cancer panel."

Summaries of three of Myriad's key poster presentations at ACMG surrounding Myriad's testing process and the Company's myVision™ variant classification program are presented below:
 
2014 ACMG – KEY POSTER PRESENTATIONS
   
Title: Align-GVGD, SIFT, Polyphen, MAPP-MMR, Grantham Analysis and Condel are weak
  predictors of the clinical significance of missense variants.
Presenter:  Iain Kerr
Date:  Friday, Mar. 28, 10:30 am to 12:00 pm CDT ( Poster 266)
Summary: This study analyzes several commonly utilized variant classification algorithms and 
  compares their performance to Myriad's proprietary variant classification program. The 
  study found that the accuracy of these algorithms was substantially lower than the 
  traditionally accepted threshold for clinical confidence.
   
   
Title:  Determining the clinical significance of silent BRCA1 and BRCA2 sequencing variants.
Presenter: Karla Bowles
Date:  Friday, Mar. 28, 10:30 am to 12:00 pm CDT ( Poster 302
Summary: Sequencing analysis of the BRCA1 and BRCA2 genes may identify mutations that are 
  predicted to be translationally silent. This study describes a testing algorithm used by 
  Myriad to determine the possible pathogenicity of silent mutations.
   
   
Title:  Assessment of laboratory-based quality control processes to ensure appropriate 
  utilization of genetic testing for hereditary cancer risk.
Presenter:  Serenedy Smith
Date: Thursday, Mar. 27, 10:30 am to 12:00 pm CDT (Poster 165)
Summary: This study evaluated BRAC Analysis ® and Colaris ® case submissions to evaluate whether 
  they met established clinical indications for testing based on patient histories. The study 
  found that only 0.5 percent of test orders lacked apparent clinical risk factors for the 
  ordered test and 93 percent met established clinical indications for testing consistent with 
  NCCN 2012 practice guidelines.
   

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo and Prolaris, Myriad myPath, Myriad myPlan, Myriad myRisk, are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments